Tony Berberabe, MPH

Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off as an in-person meeting.

Tyrosine kinase inhibitors now enjoy frontline approval, yet the role of interferon continues to be explored.

In LINKER-MM1 study, responses to REGN5458 occurred early, were durable, and deepened over time.

Although PD-L1 expression has limitations as a predictive biomarker, it has nonetheless driven clinical decision-making.

In the SIENDO clinical trials, selinexor show progression-free survival benefit in patients with select endometrial cancer subtypes.

Ajai Chari, MD, explains oncologists should expect from the upcoming 40th Annual CFS Innovative Therapy for Tomorrow.

A presentation by Richard S. Finn, MD, during the American Association for Cancer Research Special Conference, focused on phase 3 combination studies in that setting.

The superiority of the combination regimens for hepatocellular carcinoma treatment was demonstrated in results from the IMbrave150 and HIMALAYA trials, according to Josep M. Llovet, MD, PhD.

Findings from the ALCHEMIST trial indicate 53% of patients received adequate lymph node dissection and only 57% received adjuvant chemotherapy, despite indications for this treatment.

The phase 3 PADA-1 trial revealed a correlation between estrogen receptor- and progesterone receptor-positive metastatic breast cancer and prolonged progression-free survival.

Results from the DS8201-A-U105 study showed that nivolumab added to trastuzumab deruxtecan has some benefit for patients with HER2-positive breast cancer.

In the context of oncology, the use of artificial intelligence/machine learning has enabled the growth of precision medicine, helping clinicians increase efficiency and accuracy, according to Alexander S.Baras, MD, PhD.

According to study investigators, "the number of invited women panelists increased during the study period with a subsequent decrease in proportion of manels, there are topics/specialties where female representation remains stagnant."

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

Data showing the safety and efficacy of selpercatinib for patients with solid tumors continues to impress clinicians at the 2022 ASCO Annual Meeting.

An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.

In the EPCORE NHL-2 trial , epcoritamab therapy was manageable and achieved high rates of response in patients with high-risk diffuse large B-cell lymphoma.

At the upcoming 23rd Annual International Lung Cancer Congress®, Solange Peters, MD, PhD will be giving two presentation around relevant biomarkers in perioperative immunotherapy and the role of treatment agent sequencing in ALK-rearranged non–small cell lung cancer.

Thomas Flaig, MD, addressed new and emerging systemic therapies for bladder cancer during the National Comprehensive Cancer Network 2022 Annual Conference.

Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.

Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.

Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.

Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.

RP-3500 dosed at 160-mg dose on a 3 days on/4 days off continuous cycle appears to be the most tolerable for patients with selected ATR-inhibitor-sensitizing DNA damage response alterations, according to the TRESR study.

Response were observed with the combination of sotigalimab and pembrolizumab in patients with metastatic melanoma treated in a phase 1/2 study.

Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial.

Pan-immune-inflammation value made be predictive of survival benefit in patients with ALK-positive non–small cell lung cancer.

A significant proportion of patients who complete 2 years of immune checkpoint inhibitor treatment experience long-term progression-free survival.

Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.

Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.